Herantis Pharma to focus on CDNF and xCDNF programs
Herantis Pharma Plc Company release, Inside Information 29 March 2021 at 9:00 PM EET Herantis Pharma Plc (“Herantis or the Company”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative therapies, today announced that the Board of Directors has decided to focus all company resources on Herantis’ CDNF and xCDNF assets and to commence seeking out-licensing partners for the Lymfactin[®] program in the treatment of Breast Cancer Related Lymphedema (BCRL). As previously announced in a press release on March 2, 2021 that while a favourable